Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted August 14, 2008
Airborne to Pay $30 Million for Deceptive Advertising of Cold Remedy -- Refunds Available
“There is no credible evidence that Airborne products, taken as directed, will reduce the severity or duration of colds, or provide any tangible benefit for people who are exposed to germs in crowded places,” said Lydia Parnes, Director of the FTC’s Bureau of Consumer Protection.
The FTC complaint and agreed-upon final order follow settlement last November of the class-action lawsuit, Wilson v. Airborne, Inc. et al., which is pending in federal court in the Central District of California. In that case, the defendants have agreed to pay up to $23.51 million, which will be used for consumer refunds and attorneys’ fees. If the class action suit funds are exhausted, up to $6.5 million in additional funds for consumer redress will become available as a result of the FTC order. One redress administrator will manage both pools of funds and consumers will receive a single refund check.
The Wilson class action settlement provides refunds for purchases of Airborne-branded products (including Airborne Effervescent Health Formula, Airborne On-the-Go, Airborne Power Pixies, Airborne Nighttime, Airborne Jr., Airborne Gummis, and Airborne Seasonal Relief) made between May 1, 2001 and November 29, 2007. More information on the Wilson settlement, eligibility requirements, and procedures for filing a claim online or by mail can be found at www.airbornehealthsettlement.com. Consumers have until September 15, 2008 to apply for a refund for up to six product purchases.
The defendants have marketed Airborne Original Effervescent Formula as a dietary supplement containing 17 ingredients, including vitamins A, C, E, zinc, and selenium. Airborne products have been advertised nationally in print media and on radio and television. They have been sold by grocery stores, drug stores, and mass merchandisers.
According to the FTC’s complaint, there is no competent and reliable scientific evidence to support the claims made by the defendants that Airborne tablets can prevent or reduce the risk of colds, sickness, or infection; protect against or help fight germs; reduce the severity or duration of a cold; and protect against colds, sickness, or infection in crowded places such as airplanes, offices, or schools. The FTC complaint also states that the individual defendants in the case, company founders Victoria Knight-McDowell and Thomas John McDowell, made false claims that Airborne products are clinically proven to treat colds.
If consumer refund claims are not paid on time in the Wilson lawsuit, or if the defendants have not paid at least $23.5 million to settle any other similar class-action lawsuit by December 31, 2009, the defendants must pay the entire $30 million to the FTC, which will administer its own consumer redress program.